Journals / Van Tıp Dergisi / 2019 / Cilt: 26 - Sayı: 3

Incidence of Extramedullary Myeloma in Multiple Myeloma Patients

Multipl Miyelom Hastalarında Ekstramedüller Miyelom Görülme Sıklığı

Pages
337–341
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Use of more sensitive imaging techniques, EMM may be found in up to 30% of MM patients across the overall disease course.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Extramedullary myeloma (EMM) is defined by the presence of plasma cells outside the bone marrow in a patient with multiple myeloma (MM).
📊
Key Findings & Data:Use of more sensitive imaging techniques, EMM may be found in up to 30% of MM patients across the overall disease course.
💡
Conclusion & Impact:Conclusion: Extramedullary myeloma ratios were higher in our patient population than in the literature.
🔬Design:Research Article
📍Scope:2010 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Extramedullary myeloma (EMM) is defined by the presence of plasma cells outside the bone marrow in a patient with multiple myeloma (MM). Use of more sensitive imaging techniques, EMM may be found in up to 30% of MM patients across the overall disease course. We also aimed to investigate the frequency of EMM in MM patients in our clinic. Materials and Methods: Patients diagnosed with multiple myeloma in our clinic between January 2010 and August 2018 were examined retrospectively and the frequency of extramedullary myeloma was determined. Patients was divided into two groups as those with and without EMM. Factors that could be effective on these two groups were analyzed. Results: Of the 67 patients who were taken to study, 37 were male, 30 were female and the mean age was 59.9 ± 11.2. Extramedullary myeloma was detected in 31 patients (46.3%). Of these patients, 28 (41.8%) patients are bone-associated plasmacytoma, 4 (6%) patients are showed extramedullary disease. The most common bone-related plasmacytoma is the vertebrae, while extramedullary disease is most commonly seen in the lung. Conclusion: Extramedullary myeloma ratios were higher in our patient population than in the literature.

Özet

Amaç: Ekstramedüller miyelom (EMM), multipl miyelom (MM) hastalarında kemik iliği dışındaki plazma hücrelerinin varlığı ile tanımlanır. Daha duyarlı görüntüleme tekniklerinin kullanılması ile EMM, tüm hastalık seyri boyunca MM hastalarının % 30'una kadar saptanabilmektedir. Biz de kliniğimizdeki MM hastalarında EMM sıklığını araştırmayı amaçladık. Gereç ve Yöntem: Ocak 2010-Ağustos 2018 tarihleri arasında kliniğimizde multipl miyelom tanısı alan hastaların dosyaları retrospektif olarak incelenip, EMM sıklığı araştırıldı. Hastalar ekstramedüller miyelomu olanlar ve olmayanlar olarak iki gruba ayrıldı. Bu iki grup üzerinde etkili olabilecek faktörler analiz edildi. Bulgular: Çalışmaya alınan 67 hastanın 37’si erkek, 30’u kadındı ve yaş ortalaması 59,9 ±11,2 idi. Ekstramedüller miyelom 31 (% 46.3) hastada tespit edildi. Bu hastaların 28 (% 41.8)’inde kemik ilişkili plazmasitom, 4 (% 6)’ünde ekstramedüller hastalık saptandı. En sık kemik ilişkili plazmasitom vertebra da görülürken en sık ekstramedüller hastalık ise akciğerde görüldü. Sonuç: Ekstramedüller miyelom oranı hasta popülasyonumuzda literatüre göre yüksek bulunmuştur.

🔖

Cite This Article

DEMİRCİOĞLU, S., SÖNMEZ, G. M., DOĞAN, A., EKİNCİ, Ö., DEMİR, C. (2019). Incidence of Extramedullary Myeloma in Multiple Myeloma Patients. Van Tıp Dergisi, Cilt: 26 - Sayı: 3, 337–341. https://ajindex.com/articles/333893

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111(6): 2962-2972
  2. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2011; 29(28): 3805-3812
  3. Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leukemia & lymphoma 2013; 54(6): 1135-1141
  4. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27(4): 780-791
  5. Weber DM. Solitary bone and extramedullary plasmacytoma. Hematology American Society of Hematology Education Program 2005: 373-376
  6. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood 2016; 127(8): 971-976
  7. Zamagni E, Patriarca F, Nanni C, Zannetti B, Englaro E, Pezzi A, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood 2011; 118(23): 5989-5995
  8. Bartel TB, Haessler J, Brown TL, Shaughnessy JD, Jr., van Rhee F, Anaissie E, et al. F18- fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114(10): 2068-2076
  9. Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, et al. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. British journal of haematology 2015; 169(6): 851-858
  10. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21(2): 325- 330
  11. Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, et al. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. British journal of haematology 2015; 169(6): 843-850
  12. Uppal HS, Harrison P. Extramedullary plasmacytoma of the larynx presenting with upper airway obstruction in a patient with long-standing IgD myeloma. J Laryngol Otol 2001; 115(9): 745- 746
  13. Chetty R, Bramdev A, Reddy AD.